Get the Stockscreener App
1.16
2.65%
0.03
After Hours:
1.16
Anebulo Pharmaceuticals Inc stock is traded at $1.16, with a volume of 17,252.
It is up +2.65% in the last 24 hours and down -48.67% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
17,252
Relative Volume:
0.33
Market Cap:
$47.66M
Revenue:
-
Net Income/Loss:
$-7.92M
P/E Ratio:
-3.8667
EPS:
-0.3
Net Cash Flow:
$-7.05M
1W Performance:
+18.14%
1M Performance:
-48.67%
6M Performance:
-30.95%
1Y Performance:
-28.39%
1-Day Range:
$1.11
$1.19
1-Week Range:
$0.9352
$1.1959
52-Week Range:
$0.9001
$3.39
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY
Compare ANEB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANEB
Anebulo Pharmaceuticals Inc
|
1.16 | 46.43M | 0 | -7.92M | -7.05M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Trend Review: Why Anebulo Pharmaceuticals Inc stock could outperform in 2025Market Weekly Review & Safe Capital Allocation Plans - moha.gov.vn
Mereo BioPharma Group (NASDAQ:MREO) & Anebulo Pharmaceuticals (NASDAQ:ANEB) Financial Comparison - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Technicals: What valuation multiples suggest for Anebulo Pharmaceuticals Inc stock2025 Historical Comparison & Safe Entry Momentum Tips - moha.gov.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
How Is The Market Feeling About Anebulo Pharmaceuticals Inc? - Benzinga
We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely - Sahm
Anebulo shifts from reverse stock split to tender offer in go-private plan - Investing.com Nigeria
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Anebulo Pharmaceuticals stock plunges after scrapping reverse split plan By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals stock plunges after scrapping reverse split plan - Investing.com India
US Stocks Higher; Nasdaq Surges Over 100 Points - Benzinga
Anebulo Pharmaceuticals Launches Self-Tender Offer to Go Private - TipRanks
Anebulo shifts from reverse stock split to tender offer in go-private plan By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals, Inc. announces an Equity Buyback for 300,000 shares, representing 0.73% for $1.05 million. - marketscreener.com
Anebulo Pharmaceuticals Announces Self Tender Offer to Go Private - TradingView — Track All Markets
Drug developer drops reverse split, plans cash buyback to go private - Stock Titan
Is Anebulo Pharmaceuticals Inc. stock affected by interest rate hikesJuly 2025 Selloffs & Low Risk Growth Stock Ideas - Улправда
Will Anebulo Pharmaceuticals Inc. stock pay special dividendsCEO Change & Expert Curated Trade Ideas - Улправда
Why retail investors pile into Anebulo Pharmaceuticals Inc. stockQuarterly Investment Review & Stepwise Trade Execution Plans - Улправда
Why Anebulo Pharmaceuticals Inc. stock could rally in 20252025 Retail Activity & Step-by-Step Trade Execution Guides - Улправда
Can Anebulo Pharmaceuticals Inc. stock hit record highs again2025 Market Trends & Weekly Market Pulse Alerts - bolumsonucanavari.com
Will Anebulo Pharmaceuticals Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Trade Idea Sharing - Newser
Can Anebulo Pharmaceuticals Inc. stock deliver strong Q4 earningsMarket Volume Summary & Safe Capital Growth Tips - Newser
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading 0.8% HigherStill a Buy? - MarketBeat
Anebulo Pharmaceuticals (ANEB) Stock Analysis Report | Financials & Insights - Benzinga
What drives Anebulo Pharmaceuticals Inc stock priceTechnical Resistance Breaks & Exceptional Profit Growth Tips - earlytimes.in
Will Anebulo Pharmaceuticals Inc. stock deliver strong dividend growthPortfolio Return Report & Weekly High Momentum Picks - newser.com
Will Anebulo Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
Can Anebulo Pharmaceuticals Inc. stock double in next 5 yearsRate Hike & Risk Managed Investment Entry Signals - newser.com
Will Anebulo Pharmaceuticals Inc. continue its uptrend2025 Market Sentiment & Reliable Price Action Trade Plans - newser.com
Is it too late to sell Anebulo Pharmaceuticals Inc.Gap Up & Reliable Entry Point Trade Alerts - newser.com
Has Anebulo Pharmaceuticals Inc. found a price floorPortfolio Return Report & Long-Term Growth Plans - newser.com
Risk vs reward if holding onto Anebulo Pharmaceuticals Inc.July 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
How Anebulo Pharmaceuticals Inc. stock valuations compare to rivalsPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Is Anebulo Pharmaceuticals Inc. stock supported by strong cash flows2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):